Profile data is unavailable for this security.
About the company
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
- Revenue in USD (TTM)162.87m
- Net income in USD23.49m
- Incorporated2016
- Employees160.00
- LocationEntrada Therapeutics IncOne Design Center Place, Suite 17-500BOSTON 02210United StatesUSA
- Phone+1 (857) 305-1825
- Fax+1 (302) 655-5049
- Websitehttps://www.entradatx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
iTeos Therapeutics Inc | 0.00 | -135.31m | 614.45m | 157.00 | -- | 1.13 | -- | -- | -3.78 | -3.78 | 0.00 | 15.10 | 0.00 | -- | -- | 0.00 | -19.93 | 5.84 | -20.88 | 7.02 | -- | -- | -- | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
GH Research PLC | 0.00 | -35.59m | 614.45m | 49.00 | -- | 2.81 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
Grail Inc | 100.18m | -1.49bn | 615.39m | 1.36k | -- | 0.1407 | -- | 6.14 | -56.16 | -56.16 | 3.77 | 140.84 | -- | -- | -- | 74,763.43 | -- | -47.45 | -- | -48.55 | 41.91 | -- | -1,488.21 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
Astria Therapeutics Inc | 0.00 | -81.63m | 622.17m | 59.00 | -- | 2.28 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -91.06m | 623.49m | 66.00 | -- | 2.63 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 629.98m | 19.00 | -- | 6.39 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
Verve Therapeutics Inc | 16.05m | -196.83m | 630.58m | 255.00 | -- | 1.08 | -- | 39.29 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Entrada Therapeutics Inc | 162.87m | 23.49m | 632.94m | 160.00 | 27.29 | 2.14 | 23.63 | 3.89 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Celcuity Inc | 0.00 | -73.45m | 637.79m | 55.00 | -- | 4.18 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Adaptive Biotechnologies Corp | 174.50m | -215.06m | 641.05m | 709.00 | -- | 2.33 | -- | 3.67 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.3238 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Larimar Therapeutics Inc | 0.00 | -45.08m | 643.76m | 42.00 | -- | 2.79 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Applied Therapeutics Inc | -477.00k | -193.56m | 647.90m | 26.00 | -- | 9.63 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
ProKidney Corp | 0.00 | -35.30m | 651.18m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
Alumis Inc | 0.00 | -168.82m | 652.21m | 107.00 | -- | -- | -- | -- | -3.26 | -3.26 | 0.00 | 2.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 653.90m | 180.00 | -- | 2.48 | -- | 5.25 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Regenxbio Inc | 86.73m | -260.15m | 654.12m | 344.00 | -- | 1.67 | -- | 7.54 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
Holder | Shares | % Held |
---|---|---|
Baker Bros. Advisors LPas of 25 Jun 2024 | 4.87m | 13.11% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.73m | 7.35% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.31m | 3.53% |
Redmile Group LLCas of 31 Mar 2024 | 1.28m | 3.46% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.05m | 2.84% |
Wellington Management Co. LLPas of 31 Mar 2024 | 1.03m | 2.77% |
Geode Capital Management LLCas of 31 Mar 2024 | 475.36k | 1.28% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 435.39k | 1.17% |
American Century Investment Management, Inc.as of 31 Mar 2024 | 366.35k | 0.99% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 198.77k | 0.54% |